Caladrius Biosciences Inc. (CLBS) Shares Up 5.6%
Shares of Caladrius Biosciences Inc. (NASDAQ:CLBS) shot up 5.6% during trading on Monday . The company traded as high as $6.15 and last traded at $5.85, with a volume of 56,006 shares changing hands. The stock had previously closed at $5.54.
Several research firms recently issued reports on CLBS. Zacks Investment Research lowered Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Friday. Maxim Group reiterated a “hold” rating on shares of Caladrius Biosciences in a report on Saturday, May 14th. Rodman & Renshaw upgraded Caladrius Biosciences to a “buy” rating in a report on Saturday, April 30th. Finally, HC Wainwright upgraded Caladrius Biosciences from a “neutral” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Friday, April 29th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Caladrius Biosciences currently has an average rating of “Buy” and an average target price of $2.83.
The firm’s market cap is $33.65 million. The firm has a 50-day moving average price of $5.46 and a 200 day moving average price of $6.16.
In other news, Director Eric Wei sold 87,500 shares of the firm’s stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $0.60, for a total value of $52,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Caladrius Biosciences, Inc, formerly NeoStem, Inc, is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.